✦ LIBER ✦

High frequency of chronic end-stage liver disease and hepatocellular carcinoma in a Hispanic population

✍ Scribed by ADRIANA PEREZ; MONICA ANZALDUA; JOSEPH MCCORMICK; SUSAN FISHER-HOCH

Book ID: 108949735
Publisher: John Wiley and Sons
Year: 2004
Tongue: English
Weight: 84 KB
Volume: 19
Category: Article
ISSN: 0815-9319
DOI: 10.1111/j.1440-1746.2003.03277.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Frequency and predictors of de novo hepa

Frequency and predictors of de novo hepatocellular carcinoma in patients awaiting orthotopic liver transplantation during the model for end-stage liver disease era

✍ Carla W. Brady; Alastair D. Smith; Karen M. Stechuchak; Cynthia J. Coffman; Jane 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 104 KB 👁 1 views

In the current system of allocation, patients awaiting orthotopic liver transplantation (OLT) remain at risk of developing de novo hepatocellular carcinoma (HCC) and removal from the waiting list. Using the United Network for Organ Sharing database, we calculated the rate and identified predictors o

Survival after liver transplantation for

Survival after liver transplantation for hepatocellular carcinoma in the model for end-stage liver disease and pre–model for end-stage liver disease eras and the independent impact of hepatitis C virus

✍ Paul J. Thuluvath; Anurag Maheshwari; Nimisha P. Thuluvath; Geoffrey C. Nguyen; 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 248 KB 👁 1 views

It has been suggested that hepatitis C virus (HCV) patients with hepatocellular carcinoma (HCC) may have worse outcomes after liver transplantation (LT) because of more aggressive tumor biology. In this study, we determined the post-LT survival of HCC patients with and without HCV using United Netwo

High prevalence of neuropathies in patie

High prevalence of neuropathies in patients with end-stage liver disease

✍ D. Cocito; S. Maule; I. Paolasso; L. Castelli; P. Ciaramitaro; F. Poglio; A. Ott 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB

Impaired binding properties of thyroxine

Impaired binding properties of thyroxine-binding globulin in hepatocellular carcinoma and chronic liver disease

✍ Winston L. Hutchinson; Yvette S. White; Elizabeth A. Fagan; Philip J. Johnson; R 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 539 KB

To determine the factors underlying the apparent reduction in binding ability of thyroxine-binding globulin in hepatocellular carcinoma, hormonebinding characteristics were further examined in patients with this disease and in control subjects. No differences in affinity constants with respect to tr

Predicting Morbidity and Mortality After

Predicting Morbidity and Mortality After Hepatic Resection in Patients with Hepatocellular Carcinoma: The Role of Model for End-Stage Liver Disease Score

✍ Kuang-Yu Hsu; Gar-Yang Chau; Wing-Yiu Lui; Shyh-Haw Tsay; Kuang-Liang King; Chew 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 241 KB

Determination of the optimal model for e

Determination of the optimal model for end-stage liver disease score in patients with small hepatocellular carcinoma undergoing loco-regional therapy

✍ Teh-Ia Huo; Jaw-Ching Wu; Han-Chieh Lin; Fa-Yauh Lee; Ming-Chih Hou; Yi-Hsiang H 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 100 KB 👁 1 views

The model for end-stage liver disease (MELD) has been a prevailing system to prioritize cirrhotic patients awaiting liver transplantation. An "exceptional" MELD score of 20 and 24 points is assigned for stage T1 and T2 patients with small hepatocellular carcinoma (HCC), respectively. However, this s